Program:
Laboratory research over the past decade has recently begun to provide clear evidence that the
inhibition of angiogenesis is a viable therapeutic approach for a range of diseases characterized by
proliferation of vasculature including solid tumors, Kaposi's sarcoma, macular degeneration,
rheumatoid arthritis, psoriasis, and other inflammatory disorders. This program addresses the issues
surrounding the shift of angiogenesis research from theory to practice. The main focus of the meeting
is on current clinical trial results as reported by both the clinical investigator and the pharmaceutical
company. Their combined perspective will give the audience a unique overview of current clinical trial
results. Another issue focusing on the shift from theory to practice is from lead compound to drug
development to clinical trial design. As more promising leads are identified in basic research, the need
for a comprehensive drug development program including clinical trial design, regulation, and
partnering becomes evident. Any researcher working in the field of angiogenesis from basic
molecular research to those clinicians desiring information on the latest promising treatments will find
this meeting invaluable.
Registration :
Cambridge Healthtech Institute
1037 Chestnut Street
Newton Upper Falls, MA 02164 USA
Phone: 617-630-1300
Fax: 617-630-1325
Deadline for Abstracts: September 12, 1997
Email for Requests and Registration: symposia@cambridge.org